Thought Leadership

Latest Report


Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Mega-deals mask a significant decline in M&A activity for pharma and medtech The Vantage Half-Year Review 2019 summaries the most significant trends across pharma, medtech and biotech in the first half of 2019. Bristol-Myers Squibb’s $74bn pending purchase of Celgene and Abbvie’s $63bn acquisition of Allergan have taken the headlines,…

Report library


EvaluatePharma Orphan Drug Report 2018

Report Highlights Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024 The mean price of the top 100 USA orphan drugs is expected to…